Calithera Biosciences, Inc. (CALA): Price and Financial Metrics
GET POWR RATINGS... FREE!
CALA POWR Grades
- CALA scores best on the Sentiment dimension, with a Sentiment rank ahead of 93.31% of US stocks.
- CALA's strongest trending metric is Value; it's been moving down over the last 130 days.
- CALA's current lowest rank is in the Stability metric (where it is better than 2.91% of US stocks).
CALA Stock Summary
- With a market capitalization of $12,698,000, CALITHERA BIOSCIENCES INC has a greater market value than only 4.39% of US stocks.
- With a year-over-year growth in debt of -61.27%, CALITHERA BIOSCIENCES INC's debt growth rate surpasses only 4.25% of about US stocks.
- The volatility of CALITHERA BIOSCIENCES INC's share price is greater than that of 97.87% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to CALITHERA BIOSCIENCES INC are CDTX, ABUS, SYRS, CNCE, and KZIA.
- Visit CALA's SEC page to see the company's official filings. To visit the company's web site, go to www.calithera.com.
CALA Valuation Summary
- In comparison to the median Healthcare stock, CALA's price/sales ratio is 0% higher, now standing at 1.9.
- Over the past 98 months, CALA's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for CALA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CALA | 2022-11-01 | 1.9 | 0.4 | -0.1 | 0.3 |
| CALA | 2022-10-31 | 1.8 | 0.3 | -0.1 | 0.3 |
| CALA | 2022-10-28 | 1.9 | 0.4 | -0.2 | 0.3 |
| CALA | 2022-10-27 | 1.8 | 0.4 | -0.1 | 0.3 |
| CALA | 2022-10-26 | 1.9 | 0.4 | -0.1 | 0.3 |
| CALA | 2022-10-25 | 1.9 | 0.4 | -0.1 | 0.3 |
CALA Growth Metrics
- Its 3 year revenue growth rate is now at -42.87%.
- Its year over year net income to common stockholders growth rate is now at -26.07%.
- Its 3 year cash and equivalents growth rate is now at 9.53%.
The table below shows CALA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 6.75 | -60.451 | -86.296 |
| 2022-03-31 | 9.75 | -60.308 | -108.528 |
| 2021-12-31 | 9.75 | -66.3 | -115.088 |
| 2021-09-30 | 9.75 | -63.729 | -68.444 |
| 2021-06-30 | 3 | -72.425 | -80.006 |
| 2021-03-31 | 0 | -79.299 | -86.086 |
CALA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CALA has a Quality Grade of C, ranking ahead of 50.42% of graded US stocks.
- CALA's asset turnover comes in at 0.025 -- ranking 362nd of 681 Pharmaceutical Products stocks.
- BDSI, ACOR, and INSM are the stocks whose asset turnover ratios are most correlated with CALA.
The table below shows CALA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.025 | 1 | -32.536 |
| 2021-03-31 | 0.000 | NA | -6.366 |
| 2020-12-31 | 0.000 | NA | -2.320 |
| 2020-09-30 | 0.000 | NA | -1.452 |
| 2020-06-30 | 0.000 | NA | -1.002 |
| 2020-03-31 | 0.000 | NA | -0.943 |
CALA Price Target
For more insight on analysts targets of CALA, see our CALA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.00 | Average Broker Recommendation | 1.4 (Strong Buy) |
CALA Stock Price Chart Interactive Chart >
CALA Price/Volume Stats
| Current price | $0.11 | 52-week high | $13.38 |
| Prev. close | $0.10 | 52-week low | $0.07 |
| Day low | $0.08 | Volume | 299,500 |
| Day high | $0.12 | Avg. volume | 674,162 |
| 50-day MA | $1.46 | Dividend yield | N/A |
| 200-day MA | $2.88 | Market Cap | 535.15K |
Calithera Biosciences, Inc. (CALA) Company Bio
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company was founded in 2010 and is based in South San Francisco, California.
Latest CALA News From Around the Web
Below are the latest news stories about CALITHERA BIOSCIENCES INC that investors may wish to consider to help them evaluate CALA as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday! |
Calithera Biosciences Inc. (NASDAQ: CALA) Down -94.56% This Year: What Is Going To Happen NextCalithera Biosciences Inc. (NASDAQ:CALA) price closed lower on Monday, January 09, dropping -81.77% below its previous close. A look at the daily price movement shows that the last close reads $3.62, with intraday deals fluctuated between $0.63 and $0.79. The company’s 5Y monthly beta was ticking 1.75. Taking into account the 52-week price action we … Calithera Biosciences Inc. (NASDAQ: CALA) Down -94.56% This Year: What Is Going To Happen Next Read More » |
Biotech company Calithera plans its own death. Will others follow?The Peninsula company's plan to close by the end of the first quarter is atypical in a biotech industry where executives try to keep their companies alive to the next milestone in order to raise more money. |
Calithera Biosciences Stock Nosedives On Complete Liquidation, DissolutionFull story available on Benzinga.com |
CALA Price Returns
| 1-mo | -77.03% |
| 3-mo | -95.79% |
| 6-mo | -97.32% |
| 1-year | -98.92% |
| 3-year | -99.92% |
| 5-year | -99.92% |
| YTD | -96.63% |
| 2022 | -75.50% |
| 2021 | -86.45% |
| 2020 | -14.01% |
| 2019 | 42.39% |
| 2018 | -51.98% |
Loading social stream, please wait...